2022
Survival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis
Srivastava A, Patel H, Koehne E, Gupta G, Drachtman R, Pierorazio P, Bagrodia A, Elsamra S, Kim I, Ghodoussipour S, Singer E, Jang T, Patel H, Barone J. Survival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis. Urologic Oncology Seminars And Original Investigations 2022, 40: 169.e1-169.e12. PMID: 35144865, PMCID: PMC8960351, DOI: 10.1016/j.urolonc.2021.12.012.Peer-Reviewed Original ResearchConceptsNonseminomatous germ cell tumorsCancer-specific survivalGerm cell tumorsCell tumorsStage groupPediatric patientsAdolescent patientsYoung adultsStage IAdvanced nonseminomatous germ cell tumorsSurvival analysisAge groupsWorse cancer-specific survivalCox proportional hazards modelTesticular germ cell tumorsEnd Results (SEER) databaseExcellent survival outcomesStage III tumorsExcellent oncologic outcomesImportant prognostic factorKaplan-Meier curvesCommon solid malignancyProportional hazards modelNSGCT patientsOncologic outcomes
2021
Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series
Kowalczyk K, Madi R, Eden C, Sooriakumaran P, Fransis K, Raskin Y, Joniau S, Johnson S, Jacobsohn K, Galfano A, Bocciardi A, Hwang J, Kim I, Hu J. Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series. Journal Of Urology 2021, 206: 1184-1191. PMID: 34181471, DOI: 10.1097/ju.0000000000001939.Peer-Reviewed Original ResearchConceptsRobotic-assisted radical prostatectomyAssisted radical prostatectomyConsole timeRadical prostatectomyPrimary treatmentStereotactic body radiation therapyFeasible salvage optionNonsurgical primary treatmentPostoperative pad useUrinary function outcomesRisk of incontinenceKaplan-Meier curvesBody radiation therapyProportional hazards modelLonger console timeT-testStudent's t-testPostoperative complicationsMedian followupOncologic outcomesPerioperative dataBlood lossComplication rateSalvage optionFunction outcomes
2019
Immune reaction by cytoreductive prostatectomy.
Lee G, Srivastava A, Kwon Y, Kim I. Immune reaction by cytoreductive prostatectomy. American Journal Of Clinical And Experimental Urology 2019, 7: 64-79. PMID: 31139701, PMCID: PMC6526355.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerCytoreductive prostatectomyProstate cancerMetastatic diseaseCastration-resistant prostate cancerCommon non-cutaneous cancerCastration-resistant diseaseResistant prostate cancerMale cancer deathsNon-cutaneous cancerNovel treatment strategiesImmunologic changesAdvanced diseaseOncologic outcomesSurvival benefitCombinational immunotherapyCancer deathTreatment modalitiesHormonal manipulationMetastatic cancerTreatment strategiesImmune reactionsSurvival rateEffective cureCancer
2018
Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance
Dinizo M, Shih W, Kwon Y, Eun D, Reese A, Giusto L, Trabulsi E, Yuh B, Ruel N, Marchalik D, Hwang J, Kundu S, Eggener S, Kim I. Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance. Oncotarget 2018, 9: 21359-21365. PMID: 29765545, PMCID: PMC5940363, DOI: 10.18632/oncotarget.25103.Peer-Reviewed Original ResearchLow-risk prostate cancerProstate cancerWhite American menActive surveillanceAfrican American menRacial disparitiesRadical prostatectomyProstate cancer active surveillanceActive surveillance eligibilityMulti-institution databaseRisk prostate cancerUnderwent radical prostatectomyActive surveillance criteriaPositive surgical marginsTertiary care institutionSingle-institution studyMulti-institution analysisPotential racial disparitiesSignificant racial disparitiesPercentage cancerOncologic outcomesSurgical marginsHigher BMIProspective studyCancer outcomes
2017
Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy
Hong J, Kwon Y, Kim I. Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy. Asian Journal Of Andrology 2017, 19: 700-706. PMID: 28230003, PMCID: PMC5676431, DOI: 10.4103/1008-682x.193569.Peer-Reviewed Original ResearchConceptsAdjuvant radiation therapyPT3 prostate cancerRobot-assisted radical prostatectomyPathologic Gleason scoreBiochemical recurrenceRadical prostatectomyClinical progressionProstate cancerLymphovascular invasionRisk stratificationRisk factorsDisease progressionMultivariate Cox proportional regression analysisCox proportional regression analysisAdverse pathologic featuresProportional regression analysisRisk stratification toolMore risk factorsStage pT3bFree survivalOncologic outcomesPathologic featuresStratification toolGleason scoreOptimal patient
2016
Open versus robotic cystectomy: Comparison of outcomes
Davis R, Farber N, Tabakin A, Kim I, Elsamra S. Open versus robotic cystectomy: Comparison of outcomes. Investigative And Clinical Urology 2016, 57: s36-s43. PMID: 27326405, PMCID: PMC4910765, DOI: 10.4111/icu.2016.57.s1.s36.Peer-Reviewed Original ResearchConceptsRobotic-assisted radical cystectomyRadical cystectomyMuscle-invasive bladder cancerExtrapelvic lymph nodesFaster gastrointestinal recoveryLower narcotic requirementLymph node yieldInvasive bladder cancerPositive surgical marginsCurrent gold standard treatmentNumber of patientsGold standard treatmentComparison of outcomesSuperior patient outcomesRobotic surgical techniquesNarcotic requirementsPerioperative advantagesTransfusion rateGastrointestinal recoveryOncologic outcomesUrinary continenceBlood lossPostoperative qualityDistant metastasisLymph nodesLong-Term Outcomes of Using Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier Film on the Neurovascular Bundle
Patel R, Modi P, Elsamra S, Kim I. Long-Term Outcomes of Using Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier Film on the Neurovascular Bundle. Journal Of Endourology 2016, 30: 709-713. PMID: 27072291, DOI: 10.1089/end.2016.0046.Peer-Reviewed Original ResearchMeSH KeywordsCarboxymethylcellulose SodiumErectile DysfunctionHumansHyaluronic AcidKaplan-Meier EstimateLaparoscopyMaleMiddle AgedNeoplasm Recurrence, LocalPenile ErectionPostoperative PeriodProspective StudiesProstatectomyProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesRobotic Surgical ProceduresTreatment OutcomeConceptsErectile functionNeurovascular bundleBiochemical recurrenceGood baseline erectile functionPreoperative prostate-specific antigenRobot-assisted laparoscopic prostatectomyBaseline erectile functionPreoperative SHIM scoreSexual Health InventoryAUA symptom scorePostoperative erectile functionKaplan-Meier analysisNerve-sparing prostatectomyProstate-specific antigenSignificant differencesMean SHIMSHIM scoreIndependent t-testMedian followOncologic outcomesConsecutive patientsOperative timeRetrospective reviewProstate sizeSymptom scores
2015
Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer
Yu J, Kwon Y, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer. Journal Of Urology 2015, 195: 1464-1470. PMID: 26608903, PMCID: PMC5769700, DOI: 10.1016/j.juro.2015.11.031.Peer-Reviewed Original ResearchConceptsFavorable-risk prostate cancerRisk prostate cancerProstate-specific antigenProstate cancerSpecific antigenActive surveillancePathological outcomesAntigen groupRadical prostatectomyBiochemical recurrence-free survival rateElevated prostate-specific antigenProstate specific antigen cutoffLow-risk prostate cancerProstate-specific antigen levelRecurrence-free survival ratesFavorable risk diseaseMulti-institution databaseSpecific antigen levelsAdverse pathological outcomesTreatment of choiceDatabase of menHigh groupOncologic outcomesRisk diseaseAntigen levels